Clinical Trials Directory

Trials / Unknown

UnknownNCT03548766

Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping

Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Homologous/Autologous Blood Doping- a Transfusion Study

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
12 (estimated)
Sponsor
Hamad Medical Corporation · Industry
Sex
All
Age
20 Years – 50 Years
Healthy volunteers
Accepted

Summary

A total of 12 subjects will be recruited for participation in this study. 6 subjects will receive re-infusion of autologous blood, and 6 subjects (anemic patients) will receive a homologous transfusion.

Detailed description

Homologous blood transfusions (HBT) and autologous blood transfusions (ABT) are abused by athletes to illegally increase their hemoglobin mass and subsequently improve oxygen transport. Anti-Doping labs use flow-cytometry to detect HBT in cheating athletes, but athletes avoid being tested positive by matching their blood for minor blood groups before transfusion. Recent publications suggest that DNA typing by Capillary Electrophoresis or RT-PCR might be an alternative way to detect this kind of doping in athletes. Unfortunately, no data exist on the clearance of DNA after transfusion of one bag of blood using this methodology. For the detection of doping with ABT, there is no direct method available and only the biological passport, a longitudinal collection of hematological parameters can indicate doping. Recently RBC Microparticles (RBC-MPs) have been described as a potential biomarker for autologous transfusion. However, also for this methodology, no data on the clearance time of RBC-MPs are available. Thus, in this World Anti-Doping Agency (WADA) approved and sponsored project. The investigators plan to perform a clinical trial in which six healthy subjects receive an ABT and six healthy subjects or patients a HBT. Blood samples will be collected before and at several time-points after transfusion. For the detection of HBT the samples will be analyzed by the official method (cytometry), and the two genotyping methods (STR and RT-PCR) to compare these different techniques and to see if DNA-typing can replace cytometry. For the ABT the collected samples will be analyzed for RBC-MPs on a cytometer dedicated for Microparticles.

Conditions

Interventions

TypeNameDescription
BIOLOGICALHomologous Blood TransfusionHomologous, or allogenic, blood transfusions involves someone collecting and infusing the blood of a compatible donor into him/herself.
BIOLOGICALAutologous Blood TransfusionAutologous blood transfusion is the collection and re-infusion of the patient's own blood or blood components.

Timeline

Start date
2018-09-20
Primary completion
2021-12-01
Completion
2021-12-01
First posted
2018-06-07
Last updated
2020-08-11

Locations

1 site across 1 country: Qatar

Source: ClinicalTrials.gov record NCT03548766. Inclusion in this directory is not an endorsement.